Company Overview

Stevanato Group S.p.A. is an Italy-based provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company operates primarily in the healthcare manufacturing sector, with a focus on glass primary packaging, integrated drug delivery systems, and engineering solutions used in the production of injectable medicines. Its products and services are widely used in biologics, vaccines, specialty pharmaceuticals, and high-value injectable therapies.

The company’s core revenue drivers include its Biopharmaceutical and Diagnostic Solutions segment and its Engineering segment. These businesses supply pre-fillable syringes, cartridges, vials, in-vitro diagnostic consumables, visual inspection systems, assembly equipment, and production machinery for pharmaceutical manufacturers. Stevanato Group traces its origins to 1949, when Sergio Stevanato founded the company in Italy as a precision glass manufacturer. Over subsequent decades, the company expanded into pharmaceutical packaging and drug delivery technologies, evolving into a vertically integrated supplier serving major global pharmaceutical and biotechnology companies.

Business Operations

Stevanato Group organizes its activities principally through two operating segments: Biopharmaceutical and Diagnostic Solutions and Engineering. The Biopharmaceutical and Diagnostic Solutions segment manufactures glass containment systems, drug delivery devices, and diagnostic components, including EZ-fill pre-sterilized products, syringes, cartridges, and vials used for injectable therapies. The Engineering segment designs and manufactures pharmaceutical production equipment, inspection systems, and assembly machinery that support drug manufacturing and packaging processes. Revenue is generated through product sales, integrated manufacturing solutions, and long-term commercial relationships with pharmaceutical clients.

The company maintains manufacturing and operational facilities across Europe, North America, South America, and Asia. Stevanato Group controls specialized technologies related to precision glass forming, analytical testing, visual inspection, and device assembly. The company has also developed proprietary platforms for high-value biologic drug containment and delivery systems. Its operations include partnerships and customer collaborations with global pharmaceutical and biotechnology firms focused on injectable therapeutics and vaccine production. Public filings and company disclosures confirm investments in capacity expansion and integrated production capabilities intended to support large-scale pharmaceutical manufacturing demand.

Strategic Position & Investments

Stevanato Group’s strategic direction centers on expanding its role as an integrated solutions provider for injectable drug therapies, particularly in biologics, vaccines, and high-value pharmaceuticals. The company has invested significantly in manufacturing expansion, automation, and high-value containment technologies to address increasing demand for pre-fillable syringes and ready-to-use drug packaging systems. Growth initiatives have included expanding production capacity in the United States, Italy, China, and other international markets, alongside investments in advanced inspection and assembly technologies.

The company has also pursued strategic acquisitions and infrastructure investments to strengthen its engineering and drug delivery capabilities. Its portfolio includes specialized subsidiaries and manufacturing entities supporting pharmaceutical packaging and device production. Stevanato Group has increasingly focused on emerging sectors such as biologics, mRNA-related applications, and advanced injectable therapies, where sterile containment and delivery precision are critical. Public disclosures and investor materials indicate continued emphasis on high-margin, high-complexity products integrated with pharmaceutical production workflows.

Geographic Footprint

Stevanato Group is headquartered in Piombino Dese, Italy, and operates a global manufacturing and commercial network serving pharmaceutical customers across multiple continents. The company maintains a significant presence in Europe, North America, Asia, and South America, with production facilities and commercial operations strategically located near key pharmaceutical manufacturing hubs. The United States represents an important growth market, particularly for drug delivery systems and ready-to-use containment solutions.

The company’s international operations include facilities in Italy, United States, Mexico, China, Brazil, and other regions supporting pharmaceutical and diagnostic supply chains. Stevanato Group’s geographic diversification supports relationships with multinational pharmaceutical companies and reduces reliance on any single regional market. Public filings and investor presentations indicate ongoing international expansion aimed at increasing manufacturing proximity to major biopharmaceutical customers.

Leadership & Governance

Stevanato Group remains influenced by the Stevanato family, which has played a longstanding role in the company’s development and governance. The company operates under a corporate governance structure typical of publicly listed international manufacturing firms and has emphasized innovation, operational quality, and long-term pharmaceutical partnerships as part of its strategic vision. Leadership communications and public filings consistently highlight investments in high-value healthcare technologies, manufacturing scalability, and customer integration.

Key executives include:

• Franco Moro – Chief Executive Officer
• Marco Dal Lago – Chief Financial Officer
• Stefano Stevanato – Executive Chairman
• Alberto Stevanato – Chief Business Officer
• Marco De Sanctis – General Counsel

The company’s leadership strategy emphasizes long-term growth in pharmaceutical systems, expansion of global manufacturing capacity, and increased participation in biologics and injectable therapeutics markets, as reflected in public company disclosures including SEC filings and annual reports.